Pharma BD Deal Intelligence
BMS's RayzeBio unit licensed global rights to Philochem's OncoACP3, a small-molecule ligand targeting acid phosphatase 3 (ACP3) for radioligand therapy and imaging of prostate cancer, for $350M upfront and up to $1B in development, regulatory and commercial milestones plus mid-single to low double-digit royalties on global net sales. Differentiated from PSMA-targeting Pluvicto. The deal closed on August 18, 2025 following U.S. FTC clearance under the Hart-Scott-Rodino Antitrust Improvements Act; RayzeBio leads development and any commercialization. A Phase I 68Ga-OncoACP3 imaging study (NCT06840535) reached primary completion in late 2025, with an Actinium-225 therapeutic variant (225Ac-OncoACP3) advancing toward clinical testing in 2026.